News
Merck aims to boost its business by buying Verona Pharma for $10 billion. Through the deal, it will add Ohtuvayre -- a ...
The move bolsters Merck's lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.
Merck said on Wednesday it will acquire UK-based Verona Pharma for about $10 billion, gaining a promising respiratory ...
Merck is acquiring Verona Pharma for $10 billion, gaining COPD drug Ohtuvayre as part of its strategy to offset Keytruda's ...
Pharmaceutical giant Merck is buying Verona Pharma, a company that concentrates its efforts on respiratory diseases, in an ...
U.S. drugmaker Merck is nearing a deal worth about $10 billion to buy Verona Pharma, a company focused on therapies for lung ...
Merck & Co. is closing in on an approximately $10 billion deal to acquire respiratory drugmaker Verona Pharma, the Financial ...
Merck said Wednesday it would pay $10 billion to buy the biotech Verona Pharma, which sells a new lung-disease drug that ...
Verona Pharma’s flagship drug last year became the first new maintenance treatment for chronic obstructive pulmonary disease ...
Merck & Co. shares were climbing 3.1% in afternoon trading after the pharmaceutical giant announced a $10 billion deal to acquire respiratory-disease specialist Verona Pharma PLC. The deal adds Verona ...
Verona Pharma, a year after receiving regulatory approval for its landmark chronic obstructive pulmonary disease (COPD) treatment, is being acquired by pharmaceutical giant Merck in a deal worth about ...
Two Big Law firms guided Merck & Co.'s plans to purchase respiratory drugmaker Verona Pharma Plc for around $10 billion.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results